ClearBridge Investments’s Akebia Therapeutics AKBA Stock Holding History

ClearBridge Investments’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,526,790	Closed	-$20.7M	–	785
2020 Q2	$20.7M	Buy	1,526,790 +54,354	+4%	+$562K	0.02%	404
2020 Q1	$11.2M	Sell	1,472,436 -164,645	-10%	-$1.28M	0.01%	462
2019 Q4	$10.4M	Buy	1,637,081 +370,302	+29%	+$1.76M	0.01%	544
2019 Q3	$4.97M	Sell	1,266,779 -121,549	-9%	-$521K	﹤0.01%	588
2019 Q2	$6.72M	Buy	1,388,328 +130,992	+10%	+$745K	0.01%	555
2019 Q1	$10.3M	Buy	1,257,336 +41,450	+3%	+$284K	0.01%	530
2018 Q4	$6.72M	Buy	1,215,886 +199,360	+20%	+$1.56M	0.01%	558
2018 Q3	$8.98M	Buy	1,016,526 +1,016,397	+787,905%	+$9.09M	0.01%	554
2018 Q2	$1K	Buy	+129	New	+$1.29K	﹤0.01%	1121

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments's AKBA Position: Q3 2020 in Review

ClearBridge Investments sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 1,526,790 shares — an estimated $20.7M sold.

ClearBridge Investments first reported a position in AKBA in Q2 2018 and held it in 9 quarters. The position peaked at $20.7M in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

ClearBridge Investments reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
ClearBridge Investments sold 1,526,790 Akebia Therapeutics shares in Q3 2020, an estimated $20.7M.
ClearBridge Investments first reported a position in Akebia Therapeutics in Q2 2018 and held it in 9 quarters.
ClearBridge Investments's Akebia Therapeutics position peaked at $20.7M in Q2 2020.
164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on ClearBridge Investments's 13F filing for Q3 2020, filed 12 Nov 2020.